Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Lipid Res ; 56(10): 2002-9, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26254308

RESUMO

HDL is the primary mediator of cholesterol mobilization from the periphery to the liver via reverse cholesterol transport (RCT). A critical first step in this process is the uptake of cholesterol from lipid-loaded macrophages by HDL, a function of HDL inversely associated with prevalent and incident cardiovascular disease. We hypothesized that the dynamic ability of HDL to undergo remodeling and exchange of apoA-I is an important and potentially rate-limiting aspect of RCT. In this study, we investigated the relationship between HDL-apoA-I exchange (HAE) and serum HDL cholesterol (HDL-C) efflux capacity. We compared HAE to the total and ABCA1-specific cholesterol efflux capacity of 77 subjects. We found that HAE was highly correlated with both total (r = 0.69, P < 0.0001) and ABCA1-specific (r = 0.47, P < 0.0001) efflux, and this relationship remained significant after adjustment for HDL-C or apoA-I. Multivariate models of sterol efflux capacity indicated that HAE accounted for approximately 25% of the model variance for both total and ABCA1-specific efflux. We conclude that the ability of HDL to exchange apoA-I and remodel, as measured by HAE, is a significant contributor to serum HDL efflux capacity, independent of HDL-C and apoA-I, indicating that HDL dynamics are an important factor in cholesterol efflux capacity and likely RCT.


Assuntos
Transportador 1 de Cassete de Ligação de ATP/sangue , Apolipoproteína A-I/sangue , HDL-Colesterol/sangue , Idoso de 80 Anos ou mais , Transporte Biológico , Doenças Cardiovasculares/sangue , Células Cultivadas , Feminino , Humanos , Macrófagos/metabolismo , Masculino
2.
J Acquir Immune Defic Syndr ; 75(3): 354-363, 2017 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-28346318

RESUMO

OBJECTIVE: High-density lipoprotein (HDL) function rather than absolute level may be a more accurate indicator for cardiovascular disease (CVD). Novel methods can measure HDL function using patient samples. The objective of this study is to identify factors that may contribute to HDL dysfunction in chronic treated HIV-1 infection. DESIGN: Retrospective study of HDL function measured in 2 ways in HIV-1-infected men with low overall CVD risk and healthy men with no known CVD risk matched by race to the HIV-1-infected participants. METHODS: We examined patient-level factors associated with 2 different measures of HDL dysfunction: reduced antioxidant function (oxidized HDL, HDLox) and reduced HDL-apoA-I exchange (HAE), a measure of HDL remodeling, in the HIV infected and control men. Multivariable-adjusted linear regression analyses were used adjusting for false discovery rate, age, race, body mass index (BMI), CD4 count, viremia, CVD risk, smoking, lipids, apoA-I, and albumin. RESULTS: In multivariate analysis among HIV-1-infected men (n = 166) (median age 45 years, CD4 T-cell count 505 cells/mm, 30.1% were viremic), higher BMI, lower apoA-I, and lower albumin were among the most notable correlates of higher HDLox and lower HAE (P < 0.05). In HIV-1 uninfected participants, lower albumin and higher BMI were associated with lower HAE and higher HDLox, respectively (P ≤ 0.05). HDLox was inversely related to HAE in HIV-1-infected individuals (P < 0.001). CONCLUSIONS: Increased HDLox correlates with reduced HAE in chronic HIV-1 infection. Higher BMI, lower apoA-I, and albumin were identified as factors associated with HDL dysfunction in chronic HIV-1 infection using 2 independent methods.


Assuntos
Aterosclerose/sangue , Infecções por HIV/sangue , Infecções por HIV/fisiopatologia , HIV-1/imunologia , Inflamação/fisiopatologia , Lipoproteínas HDL/sangue , Adulto , Aterosclerose/virologia , Biomarcadores/sangue , Contagem de Linfócito CD4 , Estudos de Casos e Controles , Estudos Transversais , Infecções por HIV/virologia , Humanos , Inflamação/sangue , Inflamação/virologia , Masculino , Pessoa de Meia-Idade , Estresse Oxidativo/imunologia , Valor Preditivo dos Testes , Estudos Retrospectivos , Fatores de Risco , Fumar/efeitos adversos , Carga Viral
3.
PLoS One ; 10(12): e0145523, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26709509

RESUMO

Studies have suggested a link between the transforming growth factor beta 1 (TGF-ß1) signaling cascade and the stress-inducible activating transcription factor 3 (ATF3). We have demonstrated that triglyceride-rich lipoproteins (TGRL) lipolysis products activate MAP kinase stress associated JNK/c-Jun pathways resulting in up-regulation of ATF3, pro-inflammatory genes and induction of apoptosis in human aortic endothelial cells. Here we demonstrate increased release of active TGF-ß at 15 min, phosphorylation of Smad2 and translocation of co-Smad4 from cytosol to nucleus after a 1.5 h treatment with lipolysis products. Activation and translocation of Smad2 and 4 was blocked by addition of SB431542 (10 µM), a specific inhibitor of TGF-ß-activin receptor ALKs 4, 5, 7. Both ALK receptor inhibition and anti TGF-ß1 antibody prevented lipolysis product induced up-regulation of ATF3 mRNA and protein. ALK inhibition prevented lipolysis product-induced nuclear accumulation of ATF3. ALKs 4, 5, 7 inhibition also prevented phosphorylation of c-Jun and TGRL lipolysis product-induced p53 and caspase-3 protein expression. These findings demonstrate that TGRL lipolysis products cause release of active TGF-ß and lipolysis product-induced apoptosis is dependent on TGF-ß signaling. Furthermore, signaling through the stress associated JNK/c-Jun pathway is dependent on TGF-ß signaling suggesting that TGF-ß signaling is necessary for nuclear accumulation of the ATF3/cJun transcription complex and induction of pro-inflammatory responses.


Assuntos
Fator 3 Ativador da Transcrição/biossíntese , Células Endoteliais/metabolismo , Lipoproteínas/metabolismo , Receptores de Fatores de Crescimento Transformadores beta/metabolismo , Triglicerídeos/metabolismo , Transporte Ativo do Núcleo Celular , Animais , Aorta/metabolismo , Apoptose , Caspase 3/metabolismo , Células Cultivadas , Humanos , Lipólise , Lipoproteínas/genética , Camundongos , Fosforilação , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Transdução de Sinais , Proteína Smad2/metabolismo , Proteína Smad4/metabolismo , Estresse Fisiológico , Fator de Crescimento Transformador beta1/metabolismo , Triglicerídeos/genética , Proteína Supressora de Tumor p53/metabolismo
4.
Nat Rev Nephrol ; 6(6): 361-70, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20440276

RESUMO

Diabetic nephropathy is an increasingly important cause of morbidity and mortality worldwide. A large body of evidence suggests that dyslipidemia has an important role in the progression of kidney disease in patients with diabetes. Lipids may induce renal injury by stimulating TGF-beta, thereby inducing the production of reactive oxygen species and causing damage to the glomeruli and glomerular glycocalyx. Findings from basic and clinical studies strongly suggest that excess amounts of a variety of lipoproteins and lipids worsens diabetes-associated microvascular and macrovascular disease, increases glomerular injury, increases tubulointerstitial fibrosis, and accelerates the progression of diabetic nephropathy. The increasing prevalence of obesity, type 2 diabetes mellitus, and diabetic nephropathy means that interventions that can interrupt the pathophysiological cascade of events induced by lipoproteins and lipids could enable major life and cost savings. This Review discusses the structural, cellular, and microscopic findings associated with diabetic nephropathy and the influence of lipoproteins, specifically triglyceride-rich lipoproteins (TGRLs), on the development and perpetuation of diabetic nephropathy. Some of the accepted and hypothesized mechanisms of renal injury relating to TGRLs are also described.


Assuntos
Nefropatias Diabéticas/metabolismo , Nefropatias Diabéticas/fisiopatologia , Dislipidemias/metabolismo , Dislipidemias/fisiopatologia , Lipoproteínas/metabolismo , Triglicerídeos/metabolismo , Animais , Nefropatias Diabéticas/tratamento farmacológico , Dislipidemias/tratamento farmacológico , Humanos , Hipolipemiantes/uso terapêutico , Lipoproteínas/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa